NuMedii

NuMedii

Founded 2008

San Mateo, United States 5 employees Series A Total: $5.50M Biotechnology, Health and Wellness

NuMedii, founded in 2008, is a biotechnology company based in the United States. They specialize in discovering and de-risking effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The company's proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and exclusively licensed to NuMedii, consists of hundreds of millions of human, biological, pharmacological, and clinical data points. These are normalized and annotated for integration with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. The most recent investment in NuMedii was a $2.00M Series A investment on 17 August 2015. The investors in this round included Lightspeed Venture Partners, Claremont Creek Ventures, TSVC, Seraph Group, and StartX. NuMedii's approach to drug discovery and development, leveraging Big Data and proprietary algorithms, presents an innovative and potentially disruptive entry into the biotechnology industry. The recent Series A investment signifies confidence from prominent venture capital firms in the potential of NuMedii's approach and technology. With their focus on leveraging Big Data for drug development, NuMedii has the potential to address unmet medical needs and bring about novel and effective therapeutic solutions. Their strong investor backing and proprietary technology position them well for future growth and impact in the biotechnology space.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$2.00M	5	Lightspeed Venture Partners, Claremont Creek Ventures +3	17 Aug 2015
Series A	$3.50M	3	Lightspeed Venture Partners, Claremont Creek Ventures +1	26 Jun 2013

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$2.00M

Lightspeed Venture Partners, Claremont Creek Ventures +3

17 Aug 2015

Series A

$3.50M

Lightspeed Venture Partners, Claremont Creek Ventures +1

26 Jun 2013

FAQ About NuMedii

NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedi...

NuMedii was founded in 2008.

NuMedii is headquartered in San Mateo, United States.

NuMedii operates in Biotechnology and Health and Wellness. Its work centres on Drug discovery, Big Data analysis, Therapeutic success and Pharmacology.

NuMedii has approximately 5 employees.

NuMedii has completed 2 funding rounds, raising a total of $5.50M. The latest funding stage is Series A.

Top alternatives and competitors to NuMedii include Endevica Bio, Multiomic Health, Iambic, Scarlet Therapeutics Ltd, Svastia Genetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

NuMedii and Endevica Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About NuMedii

Funding Rounds & Investors (2)

NuMedii Alternatives & Competitors

FAQ About NuMedii